Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide
博士 === 國防醫學院 === 生命科學研究所 === 102 === Dendritic cells (DCs) can process and present extracellular antigens on MHC class I molecules to activate cytotoxic T lymphocyte (CTL) responses through an important mechanism, antigen cross-presentation. However, toll-like receptor (TLR)-mediated cross-presentat...
Main Authors: | Kuan-Yin Shen, 沈冠印 |
---|---|
Other Authors: | Shih-Jen Liu |
Format: | Others |
Language: | en_US |
Published: |
2014
|
Online Access: | http://ndltd.ncl.edu.tw/handle/02005787959422829416 |
Similar Items
-
Synthetic Toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants.
by: Arulkumaran Shanmugam, et al.
Published: (2012-01-01) -
Atherosclerosis induced by endogenous and exogenous toll-like receptor (TLR)1 or TLR6 agonists
by: Linda K. Curtiss, et al.
Published: (2012-10-01) -
Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
by: Kuan-Yin Shen, et al.
Published: (2020-03-01) -
Prevention and mitigation of acute radiation syndrome in mice by synthetic lipopeptide agonists of Toll-like receptor 2 (TLR2).
by: Alexander N Shakhov, et al.
Published: (2012-01-01) -
Differential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells
by: Du Yung-Ying, et al.
Published: (2011-08-01)